/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

D

David W. Hillman

Mayo Clinic(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

236

Papers

6.4K

Citations

40

h-index

79

i10-index

David W. Hillman is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Prostate Cancer Diagnosis and Treatment & Cancer Treatment and Pharmacology. The author has an h-index of 40, co-authored 201 publications.

ORCID: 0000-0002-0519-1147

Research Topics

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Cancer, Lipids, and Metabolism

Papers by this author

works

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

2015 · Journal of Clinical Oncology · 371 citations

https://doi.org/10.1200/jco.2015.62.1797

Martine Piccart Eileen Holmes José Baselga Evandro de Azambuja

<i>HER2</i> and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

2010 · Journal of Clinical Oncology · 235 citations

https://doi.org/10.1200/jco.2009.26.2154

Edith A. Perez Monica M. Reinholz David W. Hillman Kathleen Tenner

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

2020 · Journal of Clinical Oncology · 124 citations

https://doi.org/10.1200/jco.20.01276

Aranzazu Fernández-Martínez Ian E. Krop David W. Hillman Mei‐Yin C. Polley

Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer

2017 · Breast Cancer Research and Treatment · 102 citations

https://doi.org/10.1007/s10549-017-4499-7

Roberto A. Leon‐Ferre Mei‐Yin C. Polley Heshan Liu Judith A Gilbert

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

2011 · JNCI Journal of the National Cancer Institute · 78 citations

https://doi.org/10.1093/jnci/djr490

Edith A. Perez Amylou C. Dueck Ann E. McCullough Monica M. Reinholz

Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2‐positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831

2013 · Cancer · 49 citations

https://doi.org/10.1002/cncr.28130

Alvaro Moreno‐Aspitia David W. Hillman Stephen Dyar Kathleen Tenner

Research topics

topics

Prostate Cancer Treatment and Research

Prostate Cancer Diagnosis and Treatment

Cancer Treatment and Pharmacology

HER2/EGFR in Cancer Research

Cancer, Lipids, and Metabolism

Chat about Author

Papers

Chat

Click to start Chat